Biomarkers help to distinguish between dengue patients who suffer from mild Dengue Fever (DF) and those who suffer from the potentially lethal Dengue Haemorrhagic Fever (DHF)
A research team in the Infectious Diseases Interdisciplinary Research Group (ID-IRG) of the Singapore-MIT Alliance for Research and Technology (SMART) has discovered a biomarker panel that is able to predict at an early stage of the dengue fever as to who is likely to suffer from DHF, develop severe complications and require hospitalisation.
With a sensitivity and specificity of more than 80% in predicting the DHF, and a turnaround time of 48 hours (as opposed to the current triage of 4-7 days), this biomarker panel is poised to be an important part of the arsenal of tools that may help clinicians in recognising DHF early and giving appropriate patient care.
See News Release for more.
Comments